Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.81 |
| ▸ | CACNA1B | Q00975 | 7/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8150584 | 0.92 | NR1I2 (0.80) | NR1I2CACNA1BNTRK1GAANPC1 | |
| SCHEMBL8157762 | 0.89 | NR1I2 (1.00) | NR1I2CACNA1BNTRK1ALDH1A1KDM4E | |
| SCHEMBL8150105 | 0.87 | NR1I2 (0.89) | NR1I2CACNA1BNTRK1ALDH1A1KDM4E | |
| SCHEMBL3485683 | 0.87 | NR1I2 (0.74) | NR1I2CACNA1BALDH1A1GAANPC1 | |
| SCHEMBL8144766 | 0.87 | NR1I2 (0.85) | NR1I2CACNA1BNTRK1ALDH1A1KDM4E | |
| SCHEMBL8152439 | 0.87 | NR1I2 (1.00) | NR1I2CACNA1BALDH1A1GAANPC1 | |
| SCHEMBL8156552 | 0.86 | CACNA1B (1.00) | NR1I2CACNA1BALDH1A1KDM4EGAA | |
| SCHEMBL13435555 | 0.86 | NR1I2 (0.77) | NR1I2CACNA1BALDH1A1KDM4EGAA | |
| SCHEMBL8152071 | 0.84 | NR1I2 (0.84) | NR1I2CACNA1BALDH1A1GAANPC1 | |
| SCHEMBL8156334 | 0.82 | NR1I2 (0.75) | NR1I2CACNA1BALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| WO-2008133867-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | NR1I2 1761/4885CACNA1B 13/4885NTRK1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.